Navigation Links
Hard To Treat Diseases (HTDS) Completes E Europe Merger
Date:1/5/2009

CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's various merger updates where amongst other things the company addressed several targeted merger candidates, the company is pleased to announce that it has finalized its bilateral negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).

Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company, founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor to HTDS. The company research and development dates back to 2005. The institute and the physical plant is located in Belgrade Serbia. The company has been completely self funding with private resources since its inception. Over the next several weeks Slavica management and its officers intend to provide a series of filings and updates on the company's efforts and progress in this field.

Under the agreement the medical team will receive payment in stock and options on HTDS security on a delivery and performance based schedule. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a vote of confidence in Slavica and who spearheaded the transaction, shall receive no stock in this transaction and in lieu will take stock options at a .03c strike price for up to 9% of the company common stock.

In other corporate news, the company representatives intend to visit mainland China for a second merger company discussions with a China based company in a similar field and research as Slavica with a significant operations already in place in China. Upon completion of the China merger, the company intends to name its new CEO, officers and directors consisting primarily of medical professionals and business consultants.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Molecular imaging enables earlier, individualized treatment of thyroid cancer
2. Family history of prostate cancer does not affect some treatment outcomes
3. Errors involving medications common in outpatient cancer treatment
4. Hard To Treat Diseases (HTDS) Operational Update
5. Cancer drug effectively treats transplant rejections
6. Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
7. Treating gum disease linked to lower medical costs for patients with diabetes
8. Study: How Can States Treat a Sick Economy? Call the Doctors
9. Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis
10. Holiday Treats and Decorations Can Be a Deadly Combination for Pets
11. New study shows that a cough medicine ingredient could effectively treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
(Date:3/28/2017)... ... 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ... lot to offer to the discussion of dealing with excess skin oil. “Oily skin is ... home remedies that can help remove the oily shine while keeping the skin fresh and ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
Breaking Medicine Technology: